First Financial Bankshares Inc trimmed its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 48.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 115,119 shares of the medical research company’s stock after selling 109,533 shares during the quarter. First Financial Bankshares Inc’s holdings in Amgen were worth $48,524,000 as of its most recent SEC filing.
Other hedge funds also recently added to or reduced their stakes in the company. Rational Advisors Inc. raised its holdings in Amgen by 13.7% during the second quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock worth $72,000 after purchasing an additional 24 shares in the last quarter. Beacon Financial Advisory LLC grew its position in shares of Amgen by 2.0% in the 2nd quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock valued at $461,000 after buying an additional 25 shares during the last quarter. James T. Borello RIA raised its stake in Amgen by 13.6% during the 3rd quarter. James T. Borello RIA now owns 209 shares of the medical research company’s stock worth $88,000 after acquiring an additional 25 shares in the last quarter. Sweeney & Michel LLC raised its stake in Amgen by 0.5% during the 3rd quarter. Sweeney & Michel LLC now owns 5,129 shares of the medical research company’s stock worth $2,162,000 after acquiring an additional 25 shares in the last quarter. Finally, Legacy Financial Advisors Inc. raised its stake in Amgen by 0.8% during the 2nd quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock worth $1,234,000 after acquiring an additional 26 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.
Amgen Stock Down 0.7%
AMGN stock opened at $462.32 on Tuesday. The company has a fifty day moving average price of $425.81 and a 200 day moving average price of $381.77. Amgen Inc. has a 12 month low of $312.39 and a 12 month high of $483.99. The company has a market cap of $250.07 billion, a price-to-earnings ratio of 20.15, a price-to-earnings-growth ratio of 3.25 and a beta of 0.43. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.20.
Amgen (NASDAQ:AMGN – Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, topping analysts’ consensus estimates of $5.79 by $0.66. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The firm had revenue of $10.37 billion during the quarter, compared to analysts’ expectations of $10.07 billion. During the same quarter in the prior year, the business earned $5.64 EPS. Amgen’s quarterly revenue was up 8.5% compared to the same quarter last year. Sell-side analysts expect that Amgen Inc. will post 23.37 earnings per share for the current year.
Amgen Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be paid a dividend of $2.52 per share. The ex-dividend date is Friday, November 20th. This represents a $10.08 annualized dividend and a dividend yield of 2.2%. Amgen’s dividend payout ratio is 58.47%.
Wall Street Analysts Forecast Growth
A number of brokerages recently weighed in on AMGN. Barclays upped their price objective on shares of Amgen from $400.00 to $430.00 and gave the company an “equal weight” rating in a research note on Monday. Bank of America lifted their target price on Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 5th. UBS Group lifted their target price on Amgen from $470.00 to $530.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. The Goldman Sachs Group boosted their target price on Amgen from $481.00 to $536.00 and gave the company a “buy” rating in a report on Wednesday, November 4th. Finally, Robert W. Baird upped their target price on Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $425.69.
Read Our Latest Report on Amgen
About Amgen
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
Featured Stories
- Five stocks we like better than Amgen
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
